Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy

NCT02689986 is registered in ClinicalTrials.gov with Helse Fonna as lead sponsor.

NCT NCT02689986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02689986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy
Lead sponsor
Helse Fonna
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
December 31, 2016
Enrollment
43 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia, cold agglutinin disease